CCL2 is a key chemokine in monocyte recruitment, and inhibitors of the CCL2–CCR2 axis (e.g., bindarit, CCX872) have demonstrated renoprotective effects in diabetic kidney disease by reducing macrophage infiltration and inflammation. Here, CCR2 is linked to diabetic kidney disease.